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Abstract
In general, carbohydrate–lectin interactions are characterized by high specificity but also low affinity. The main reason for the low
affinities are desolvation costs, due to the numerous hydroxy groups present on the ligand, together with the typically polar surface
of the binding sites. Nonetheless, nature has evolved strategies to overcome this hurdle, most prominently in relation to carbohy-
drate–lectin interactions of the innate immune system but also in bacterial adhesion, a process key for the bacterium’s survival. In
an effort to better understand the particular characteristics, which contribute to a successful carbohydrate recognition domain, the
mannose-binding sites of six C-type lectins and of three bacterial adhesins were analyzed. One important finding is that the high
enthalpic penalties caused by desolvation can only be compensated for by the number and quality of hydrogen bonds formed by
each of the polar hydroxy groups engaged in the binding process. In addition, since mammalian mannose-binding sites are in
general flat and solvent exposed, the half-lives of carbohydrate–lectin complexes are rather short since water molecules can easily
access and displace the ligand from the binding site. In contrast, the bacterial lectin FimH benefits from a deep mannose-binding
site, leading to a substantial improvement in the off-rate. Together with both a catch-bond mechanism (i.e., improvement of affinity
under shear stress) and multivalency, two methods commonly utilized by pathogens, the affinity of the carbohydrate–FimH interac-
tion can be further improved. Including those just described, the various approaches explored by nature to optimize selectivity and
affinity of carbohydrate–lectin interactions offer interesting therapeutic perspectives for the development of carbohydrate-based
drugs.
Review
Recognition of carbohydrate ligands
For the recognition of carbohydrate ligands, nature has explored
binding sites of different shapes and properties. The large
family of C-type lectins (CLECs) exhibits carbohydrate-recog-
nition domains (CRDs) which incorporate a calcium ion [1-4].
CLECs are involved in a wide range of biological processes,
such as pathogen recognition and intercellular adhesion [5-7]. A
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large number of CLEC structures, including animal, plant and
bacterial lectins, are available in the Protein Data Bank [8]. A
second large family of lectins, the bacterial adhesins, play an
important role in the initial interaction of the bacterium with
host tissue [9,10]. This primary contact is a prerequisite for the
infection of host cells and subsequent biofilm formation, and
grants the bacteria a significant advantage by resisting clear-
ance and killing by immune factors, bacteriolytic enzymes, or
antibiotics.
In this review, with focus on lectins relevant for drug discovery
and development, the mannose-binding sites of six CLECs and
three bacterial lectins are analyzed and compared with one
another to answer the question: What makes for a successful
mannose recognition domain? In general, lectins are character-
ized by high ligand specificity, whereas the affinity for their
carbohydrate ligands is comparatively low. A prominent exam-
ple is sialyl Lewisx (sLex), a tetrasaccharide typically O-linked
to cell surfaces and known to play a vital role in cell-to-cell
recognition processes [11]. Although highly specific, its interac-
tion with E-selectin exhibits a dissociation constant (KD) of
only 800 μM [12]. To address this obstacle of low affinity,
nature applies the principal of multivalency by providing
several binding sites to the carbohydrate ligand and/or a multi-
valent display of the ligand [13-15]. This accumulation of indi-
vidual binding events increases the overall binding strength
either by avidity or local concentration effects [16,17]. How-
ever, other approaches, such as the reduction of desolvation
costs or ligand and binding site pre-organization, are more diffi-
cult to assess and accordingly have been highlighted in this
review.
Mannose-binding CLECs are involved in various pathways of
the human innate immune response, including the blood
dendritic cell antigen 2 (BDCA-2, also known as CD303) [18],
langerin (CD207) [19,20], pulmonary surfactant-associated pro-
tein D (SP-D) [21], dendritic cell-specific ICAM-3-grabbing
non-integrins 1 and 2 (DC-SIGN, also known as CD209; and
DC-SIGNR, also known as CD299) [22,23], and mannose-
binding protein (MBP) [24]. These CLECs exert their function
through different mechanisms, for instance by pathogen inter-
nalization as in the case of BDCA-2 and langerin, by pathogen
opsonization as mediated by SP-D and MBP, or by T-cell inter-
actions as mediated by DC-SIGN and DC-SIGNR [25,26].
In contrast, pathogens have developed numerous adhesins that
mediate their interaction with glycosides on mammalian cell
surfaces. After this initial contact, they can infect host cells and
form biofilms, both of which are key factors for their survival
[9,27,28]. Examples of such opportunistic bacterial species
binding to mannosides on host cells include Pseudomonas
aeruginosa with its membrane lectin LecB [29,30] and Burk-
holderia cenocepacia with its characteristic B. cenocepacia
lectin A (BC2L-A) [31,32], both playing an important role in
the social life of bacterial cells. A further example is the bacteri-
al adhesin FimH, which plays a crucial role in urinary tract
infections (UTIs). FimH enables uropathogenic Escherichia coli
(UPEC) to adhere to urothelial host cells [33,34], which repre-
sents the first and most critical step in UTI, triggering a cascade
of pathogenic processes ultimately leading to infection. The
ligand on urothelial cells binding to the N-terminal lectin
domain of FimH is the highly mannosylated glycoprotein
uroplakin 1a (UPIa) [35,36]. The binding pocket of FimH
accommodates a single α-D-mannose (1) with an extended
hydrogen-bond network [37,38]. Accordingly, any modifica-
tions on the hydroxy groups of the mannose virtually abolish
binding affinity [37-39].
Crystal structures of mannose–lectin
complexes
The X-ray structures of six mannose-binding receptors
in complex with either α-D-mannose (1) or methyl α-D-manno-
pyranoside (2) were analyzed (Figure 1 and Table 1, A–C and
G–I). Since for DC-SIGNR (Figure 1, D) and DC-SIGN
(Figure 1, E) neither complexes with 1 nor 2 were available, we
instead modeled the monosaccharide–receptor interactions
based on the available oligomannose crystal structures (PDB
codes: 1K9J and 1SL4). In addition, because none of the avail-
able crystal structures of human MBP met our threshold of a
resolution below 2 Å, we used a structure based on a homolo-
gous MBP lectin domain from Rattus norvegicus and accord-
ingly compared the measured binding affinity of rat MBP
(Figure 1, F). Finally, a special case is the bacterial adhesin
FimH, which can adopt three different affinity states (see
below). For our discussion we focus specifically on the high-
affinity state of FimH present in the isolated lectin domain of
FimH, called FimHLD (Figure 1, I).
Although the receptors A–F play important roles in human
immune responses, they exhibit affinities only in the millimolar
range (9.4–1.3 mM) for α-D-mannose (1) and methyl
α-D-mannopyranoside (2) [40-44]. In contrast, the receptors G
and H of bacterial origin show affinities in the micromolar
range (71 and 2.8 µM, respectively) for methyl α-D-mannose
(2) [31,45]. Despite the 71 µM affinity, LecB (G) preferably
binds L-fucose (3 µM) and methyl α-L-fucoside (0.4 µM) [45].
The enhanced affinity for fucosides originates from the
C5-methyl group, absent in both 1 and 2, which can form a
hydrophobic contact with Thr45 [45].
The analyzed CLECs A–F share a common binding motif, with
a calcium ion coordinating to O–C3 and O–C4 of the mannose
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
2586
Figure 1: CRDs of the analyzed crystal structures, with mannose pyranosyl units similarly aligned in each structure. Mammalian lectins: (A) BDCA-2,
(B) langerin, (C) SP-D, (D) DC-SIGNR, (E) DC-SIGN, (F) rat MBP; bacterial lectins: (G) LecB, (H) BC2L-A, and (I) FimH lectin domain.
ligand [5,7]. In instances where the binding site hosts a second
calcium ion (G and H), advantageous interactions between
O–C2 and O–C3 can also occur. Additional contributions from
H-bonds formed in the buried binding pockets further improve
affinity. In contrast, the calcium-free, buried binding site of the
bacterial lectin FimH (I) forms a complex network of eight
hydrogen bonds with ligand 2, one of them mediated by a
conserved water [37].
Various approaches to realize binding affinity
The immense variability of binding affinities among mannose-
binding receptors is remarkable, albeit not surprising. While
CRDs involved in the human immune system (Table 1, A–F)
recognize a broader spectrum of binding partners (i.e., various
pathogenic oligosaccharides), bacterial CRDs G–I strive for
tight binding to host glycans to improve their chances of
survival. To achieve these enhanced affinities, pathogens
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
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Table 1: Crystal structures of mannose-binding lectins, and their affinity for α-D-mannose (1) or methyl α-D-mannopyranoside (2).
lectin target affinity [µM] ligand efficiency PDB code resolution [Å] reference
A BDCA-2 9.4 × 103 a 0.22 4ZES 1.65 [40]
B langerin 4.4 × 103 a 0.25 4N37 2.00 [41]
C SP-D 3.8 × 103 b 0.28 3G81 1.80 [42]
D DC-SIGNR 2.5 × 103 b 0.30 1K9Jc 1.90 [43,46]
E DC-SIGN 2.3 × 103 b 0.31 1SL4c 1.55 [22,43]
F rat MBP 1.3 × 103 b 0.34 1KWU 1.95 [44,47]
G LecB 71a 0.45 1OUR 1.42 [29,45]
H BC2L-A 2.8a 0.60 2VNV 1.70 [31]
I FimHLD 1.2a 0.61 5JCQ 1.60 [48]
aAffinity of methyl α-D-mannoside (2); baffinity of α-D-mannose (1); cmodified oligopyranomannose crystal structure.
Figure 2: A) The solvent exposed binding site of E-selectin interacting with sLex (PDB: 1G1T) [53]. B) The buried binding site of FimHLD in complex
with a high-mannose epitope and a conserved water (blue sphere) (PDB: 2VCO) [36]. C) The buried ligand surface area of analyzed crystal struc-
tures correlates to affinity [μM] on a logarithmic scale (for references see Table 1). The rabbit and turtle metaphor was adapted from Schmidtke et al.
[50].
apply a variety of strategies such as binding sites with
minimal solvent-exposed surface areas, increased number of
ligand interactions, “shared” desolvation costs, and multiva-
lency.
Degree of solvent exposure in the binding site (Figure 2).
Because of the electrostatic character of H-bonds, the dielectric
constant ε becomes especially important in carbohydrate–lectin
interactions. In buried cavities of the binding site, ε is lower
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
2588
(ε ≈ 5–10) compared to protein surfaces (ε ≈ 20) or bulk water
(ε ≈ 80), making an H-bond thermodynamically up to 10-fold
more valuable in buried cavities [49]. This at least partially
explains the generally weak interactions of carbohydrates that
bind on the solvent exposed surface of proteins, as compared to
those of the majority of marketed drugs that most frequently
bind to protein cavities. Additionally, buried and less solvent
exposed ligands show slower exchange rates, characterized by a
high-energy transition state. This can be explained by the step-
wise dissociation and subsequent rehydration that are required
for ligand displacement (inset, Figure 2B), due to the inherently
shielded nature of the buried binding site. In contrast, solvent
exposed H-bonds can be more easily substituted by surround-
ing water molecules in a concerted, bimolecular process (inset,
Figure 2A), resulting in faster off-rates and therefore poor phar-
macodynamics [50,51]. Similarly, water molecules in buried
binding sites show residence times in the micro- to nanosecond
range as opposed to surface water molecules which exhibit
short residence times in the low picosecond range [52].
Whereas E-selectin in complex with sLex is an excellent exam-
ple of a solvent exposed interaction [12,53], the interaction of
FimHLD with mannosides well illustrates the counter situation
for a deep CRD [36] (Figure 2A and B, respectively). This
difference in solvent exposure leads to considerably different
residence times for their physiological ligands. Whereas sLex
has a residence time of less than a second, the natural substrate
of FimHLD (I) displays a residence time of more than a minute,
and for some synthetic FimHLD antagonists even longer
[48,54].
Among the analyzed CLECs A–F and bacterial lectins G–I,
affinity increases with a decrease in solvent exposure of the
binding site (Figure 2C). The buried ligand surface area, an al-
ternative way of expressing solvent exposure of the binding site,
is between 160–180 Å2 for A–F, 228 Å2 for G, 262 Å2 for H,
and 310 Å2 for I. The decreased dielectric constant ε in the deep
cavities of H and I, as well as the resulting occlusion of the
ligand from surrounding water molecules, leads to a more stable
hydrogen-bond network and thus to higher affinities. Further-
more, the binding site of F features the aromatic His189, that
can engage in CH–π interactions, associated with contributions
to the binding affinity in the range of 0–6.3 kJ/mol [55,56].
Analysis of the dynamics of mannose–lectin interactions
(Figure 3). In a next step, the stability of H-bond and metal
interactions, as well as the influence of highly mobile vs
conserved waters were analyzed. For the assessment of the
dynamic behavior of the ligand complexes of the seven
calcium-dependent lectins, 20 ns molecular dynamics (MD)
simulations were performed [57]. The most prominent interac-
tions of O–C3 and O–C4 of the mannose moiety with the
calcium ion of CLECs A–F were stable throughout the entire
simulation [5,7]. With the bacterial lectins LecB (G) and
BC2L-A (H) each featuring two calcium ions the carbohydrate
ligand forms up to four interactions: O–C2 and O–C4 provide
one each, while O–C3 engages with both calcium ions.
Figure 3: Dynamic mannose–receptor interactions (20 ns MD simula-
tions), grouped according to the nature of the interaction. Metal inter-
actions with Ca2+ are colored in purple, hydrogen bonds highlighted in
yellow, and water-mediated interactions in cyan. (A) BDCA-2,
(B) langerin, (C) SP-D, (D) DC-SIGNR, (E) DC-SIGN, (F) rat MBP,
(G) LecB, (H) BC2L-A, (I) FimHLD.
During MD simulations, the number of ligand–protein hydro-
gen-bond interactions for lectins A–F varied from 1.5 to 3.5,
and subsequently increased to 4.5 and 5.4 for LecB (G) and
BC2L-A (H), respectively. Lastly, FimH (I) forms on average
7.9 hydrogen bonds with methyl α-D-mannopyranoside (2). For
H-bonds that were only partially present during the MD simula-
tion, non-integer numbers of hydrogen bonds arise.
The number of water-bridged H bonds between ligand and
lectin varied greatly (Figure 3), from 0.1 to 2.4 for the buried
binding site of BC2L-A (H) versus the solvent exposed binding
site of SP-D (C), respectively. Interestingly, although the struc-
turally similar bacterial CRDs of G and H differ by only one
amino acid in the β8-β9-loop, a large impact on the number of
water-mediated H-bonds was observed. Thus, Thr98 in the bac-
terial lectin G allows for the entry of a water molecule close to
the first calcium ion, a process which is hindered by His112 in
H, leading to a 25-fold difference in affinity. However, in the
case of highly mobile water molecules, water-mediated
H-bonds as observed in MD simulations destabilize the carbo-
hydrate–lectin interaction, whereas a pre-constrained water
molecule does not lead to an additional entropy penalty upon
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Figure 5: Model view of the binding site interactions of DC-SIGN (E) and BC2L-A (H) with water. A) The solvent exposed binding site of E illustrates
two water molecules (w1 and w2) interacting with a single calcium ion, and the cost of desolvation for these waters. B) The buried binding site of H
exhibits three water molecules (w1–3) bound to two calcium ions, together with their respective desolvation costs.
H-bonding to the ligand. As a result, the interaction benefits
from an enthalpic gain without suffering from an entropic
penalty [58]. Examples of such highly conserved water mole-
cules are found in both, L-arabinose binding protein (ABP) [59]
and FimH (I), where in the latter the water mediated H-bond
originates solely from one stable water interacting with O–C2
(Figure 2B).
The cost of desolvating hydroxy groups (Figure 4).
In general ,  when the low aff ini ty issue regarding
carbohydrate–lectin interactions is discussed, the costs of desol-
vation are often neglected. Because of the large number of
hydroxy groups present in carbohydrate ligands, and the polar
amino acid side chains of the lectin binding sites, desolvation
generates an essential enthalpic penalty which can hardly be
compensated for by the newly formed electrostatic interactions
[60]. Cabani et al. calculated that the desolvation of an isolated
hydroxy group causes an enthalpic penalty of ΔH = 35 kJ/mol,
which is slightly reduced by a beneficial entropic term of
ΔS = 10 kJ/mol due to the release of solvating water molecules
into bulk [61]. As a result, the desolvation penalty for one
hydroxy group amounts to ΔG = 25 kJ/mol (Figure 4A) and
cannot be compensated for by a single hydroxy H-bond, which
has been associated with a maximal energy gain of approxi-
mately ΔG = 18 kJ/mol [62,63]. However, for vicinal hydroxy
groups as are present in carbohydrate ligands, the overall desol-
vation penalty is slightly reduced resulting in an overall desol-
vation cost of ΔG = 34 kJ/mol for both hydroxy groups
(Figure 4B). Since carbohydrates in general exhibit a number of
adjacent hydroxy groups, their desolvation penalties are diffi-
cult to assess but it is most likely that each additional hydroxy
group would not contribute the maximum penalty associated
with an isolated one.
Figure 4: Desolvation of hydroxy groups. A) The desolvation cost of a
single hydroxy group associated with three water molecules is
ΔG = 25 kJ/mol, as calculated by Cabani et al. [61]. B) the desolvation
cost of two adjacent hydroxy groups associated with five water mole-
cules is ΔG = 34 kJ/mol, as opposed to 50 kJ/mol (equal to twice
25 kJ/mol). This can be explained by water w3, which is shared be-
tween the two hydroxy groups.
The cost of desolvating calcium ions (Figure 5). Oppor-
tunistic bacteria such as Pseudomonas aeruginosa or Burk-
holderia cenocepacia have incorporated a second calcium ion
into their binding site, coordinating three water molecules
which are released into bulk water upon mannose binding and
thereby contribute to a favorable entropic effect. The cost to
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
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remove one water molecule from a calcium–malonate model
system was calculated quantum mechanically (QM) to be
56.9 kJ/mol by Charifson et al. [64]. This is in agreement with
electrospray mass spectrometry experiments from Blades et al.,
who reported water–calcium interaction energies in the range of
62.8 kJ/mol [65]. In-house QM calculations, based on binding
site models of DC-SIGN (E) and BC2L-A (H) (Figure 5),
suggest that the average desolvation cost of a single water mole-
cule coordinated to the calcium ion (calculated as a simple
difference of the electronic energies of three molecular species:
Edesolv = Ereceptor···water − Ereceptor − Ewater) is approximately
77 kJ/mol [66]. Interestingly, the calculated desolvation penalty
per calcium ion is more favorable for the binding site of H
(113 kJ/mol per Ca2+), as compared to the one for E
(159 kJ/mol per Ca2+). Similar to the observations made for
vicinal hydroxy groups, the rather high desolvation penalty of
two calcium ions in the cases of LecB (G) and BC2L-A (H)
(Figure 5B), is in fact reduced when compared to the sum of
desolvating two individual calcium ions, again a result of them
sharing a common water molecule.
However, the absolute values of the calculated desolvation
energies strongly depend on the local environment of each
water molecule. For example, w3 in the binding site of
BC2L-A (H) exhibits a desolvation energy of 89.6 kJ/mol due
to the additional interactions to a glutamate and w2. On the
other hand, w1 in the exact same binding site is the least costly
among the three waters, as it forms fewer interactions and its
loss can also be partially compensated by w2 (Figure 5B).
Profiling the pharmacodynamic difference in binding sites.
A comparison of the thermodynamic fingerprints of sLex inter-
acting with the solvent exposed CRD of E-selectin versus
n-heptyl α-D-mannoside bound to the buried binding pocket of
FimHLD (I) represent two different binding scenarios
(Figure 2A and B). With the entropically driven sLex interac-
tion, surface waters are displaced to the bulk and penalized by a
positive enthalpy term resulting from a desolvation penalty that
is not compensated by the newly formed electrostatic interac-
tions (Figure 6) [67]. According to Dunitz [68], the entropy that
can be gained by such waters ranges from 0 kJ/mol for highly
mobile waters to 8 kJ/mol for ordered and firmly bound waters.
In contrast, the thermodynamic fingerprint of FimH ligands is
enthalpically driven because an optimized, stable H-bond
network is formed, and as a result, overcompensates the desol-
vation penalty [69,70].
Pre-organization vs flexibility. Carbohydrate–lectin interac-
tions benefit from the low conformational flexibility of pyra-
noses. This could be impressively demonstrated in a case study
comparing a septanose with a manno-configured pyranose de-
Figure 6: Thermodynamic fingerprints of sLex bound to E-selectin and
n-heptyl α-D-mannoside bound to FimHLD (I). The sLex–E-selectin
interaction is entropically driven, whereas the n-heptyl α-D-manno-
side–FimHLD (I) is enthalpically driven.
rivative [71]. Although in both cases an identical H-bond
network with the conformationally rigid FimHLD (I) was estab-
lished, the higher flexibility of the seven-membered ring
septanose led to a 10-fold loss in affinity. In fact, the number of
possible solution conformations was considerably higher for the
septanose ligand as compared to the six-membered ring coun-
terpart, effectively increasing the entropic cost of binding to
FimHLD (I), while the enthalpic fingerprint observed for both
ligands was identical.
However, depending on its needs, UPEC can vary the confor-
mational state of FimH. In the unbound state, FimH exhibits the
low-affinity conformation (Figure 7A), which upon binding to
mannose, switches to the medium-affinity conformation
(Figure 7B). In this state, weak interactions are beneficial
because the bacterium can still easily dissociate (slip-bond be-
havior) and explore its surroundings for optimal nutrient supply.
During voiding of the bladder, shear force acts on the FimH
protein and pulls the lectin domain (FimHLD) away from the
pilin domain (FimHPL), inducing the high-affinity conforma-
tion (Figure 7C), which exhibits an approximate 100-fold
higher affinity. Generally, this type of shear force-dependent
adhesive bond is known as a catch-bond and in the case of
UPECs enables them to evade clearance during micturition.
When shear force ceases, FimH reverts back to the equilibrium
between low-affinity and medium-affinity conformations [72].
In general, flexible receptors are associated with higher entro-
pic costs resulting from induced-fit binding, which also corre-
lates to facilitated ligand dissociation: due to increased water
exposure, the residence time of flexible ligand–lectin com-
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
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Figure 7: Schematic overview of the conformational changes of FimH (I). FimH crystal structures, which correspond to each individual state are
shown in boxes. In the absence of urine flow FimH is in the low-affinity conformation, characterized by an open binding pocket and intertwined
domains (A, PDB: 4XOD). Upon ligand binding, FimH adopts the medium-affinity conformation (B, PDB: 4XOE), in which a loop (highlighted in green
in the crystal structures) closes in the ligand, forming a deep and well-defined binding pocket. As urine begins to flow, the two domains are pulled
apart, inducing the high-affinity conformation (C, PDB: 4XOB). LD, lectin domain; PD, pilin domain [72].
plexes is shortened [51]. A comparison of the apo crystal struc-
tures of BDCA-2 (A) and LecB (G) (PDB codes: 3WBP [73]
and 1OUX, respectively) to their holo forms excellently demon-
strates the entropic costs generated by receptor flexibility.
Whereas the binding site of the bacterial lectin G does not
undergo conformational changes upon ligand binding (RMSD:
0.3 Å; Figure 8A), a conformational change involving a binding
site loop allows for the formation of a homodimer of A
(Figure 8B) [40]. It is believed that this dimer enables transport
of the lectin from the Golgi apparatus to cell membranes [73].
Due to a dislocated glutamate in the side chain of the homo-
dimer (Figure 8B), the affinity for calcium binding and there-
fore also carbohydrate binding is extensively reduced. This
remarkable form of inactivation is only possible due to loop
flexibility. However, it is also the origin of the low affinity
(9.4 mM) towards methyl mannoside (2) due to entropic costs
associated with the formation of the binding site.
Multivalency. Dam and Brewer reviewed the role of density
and number of glycan epitopes involved in multivalent carbohy-
drate interactions for legume lectins as well as for lectins of the
innate immune system [74]. As an example, HIV-1 establishes
multivalent contacts to DC-SIGN (E)-decorated dendritic cells
in order to bypass host immune attack. Thus, DC-SIGN plays a
key role in the dissemination of HIV-1 by capturing of HIV-1 at
entry sites of infection and subsequent transport of the virus to
CD4+ T cells in lymphoid tissues. The weak monovalent
binding affinity of DC-SIGN (E) is compensated for by a multi-
valent display of oligomannosides on viral envelop glyco-
protein gp120, facilitating stronger adhesion between dendritic
cells and HIV-1 [43,75,76]. This multivalent binding interac-
tion results in an enhancement in binding by several orders of
magnitude, from a KD of 26 μM for monovalent Man9GlcNAc2,
as compared to 1.7 nM for glycosylated gp120 (25 glycosyla-
tion sites) [43,77]. In the case of UPEC, each bacterium
Beilstein J. Org. Chem. 2017, 13, 2584–2595.
2592
Figure 8: Comparison of the holo (white) and apo (green, magenta) binding sites of LecB (G) and BDCA-2 (A), respectively. A) The superimposition
of both binding sites of G reveals nearly identical structures (RMSD of 0.3 Å). B) The binding site of A exhibits a flexible loop which enables homo-
dimerization (chain A in green and chain B in magenta), in which a glutamate residue that is essential for Ca2+ binding ends up projecting away from
the binding site (illustrated for chain A). The situation is mirrored for chain B. Interestingly the loop from chain B closely mimics the binding site of the
holo structure (white).
contains three to five hundred fimbriae to potentiate multiva-
lency, as each FimHLD (I) at the fimbrial tip can interact with
mammalian UPIa [78].
Multivalent glycosides have also been investigated in the
context of a novel therapeutic approach against viral and bacte-
rial infections [79]. However, carbohydrate valency, spacing,
and branching all need to be thoughtfully considered with this
class of therapeutics [15,80].
Conclusion
Mannose-recognizing lectins fulfill a myriad of purposes and
depending on the particular biological role either high selec-
tivity and/or high affinity can be required.
On the one hand, lectins of the human immune system tend to
exhibit lower affinities due to a higher degree of solvent expo-
sure of their CRDs: fewer H-bond interactions can barely
compensate for the high desolvation penalties and constrain-
ment of flexible loop motifs which together contribute to a sig-
nificant energy penalty upon binding. Nonetheless, these quali-
ties enable ligand promiscuity and can facilitate other features
such as the inactivation via homodimerization as exemplified in
BDCA-2.
In contrast, bacterial lectins are under constant pressure for
survival, hence multiple strategies to ‘get it right the first time’
are employed. For example, the desolvation of a binding site
containing two calcium ions costs 113 kJ/mol/Ca2+ and there-
fore is less costly per calcium ion than a binding site containing
only a single ion (159 kJ/mol/Ca2+; Figure 5). However, in the
binding site containing two calcium ions, the ions are able to
establish four interactions with the carbohydrate ligand, where-
as in the latter example the number of interactions is reduced to
two. This leads to an overall enthalpic benefit by forming addi-
tional interactions at a reduced cost. In addition, the entropy
gained by releasing three water molecules into bulk, as com-
pared to only two, should also be taken into account.
The formation of multiple H-bonds in rigid, buried binding sites
is an alternative way to gain enthalpy, and thereby increase
affinity. UPEC perfects this approach with the calcium-devoid
binding site of FimHLD (I). A possible explanation for the lack
of a calcium ion in the FimH binding site may relate to the
slight acidity of urine (pH 5.5–7.0), with a calcium clearance of
20–300 mg/day [81]. Calcium-dependent lectins require a non-
acidic environment, such as found in blood, since at lower pH
the glutamate and/or aspartate side chains essential for calcium
binding can become partially protonated. Instead, FimHLD
forms an extensive hydrogen-bond network in a buried, rigid
binding site, which lowers the dielectric constant resulting in
better shielded, stronger hydrogen bonds, and also reduces the
entropic penalty of binding [82]. In addition, the recently de-
scribed catch-bond behavior of FimHLD is responsible for a
100-fold increased affinity under selective pressure [70,83].
Together with the multivalency of the interaction this results in
the high affinity of 2 to FimHLD (I).
The examples apparent in nature of effective mannose recogni-
tion domains rely on a combination of partially opposed effects.
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They nevertheless offer interesting perspectives for the develop-
ment of carbohydrate-based drugs. One such example of a ther-
apeutic application can be found in a recent novel approach to
treating anti-myelin-associated glycoprotein (anti-MAG)
neuropathy, a rare, disabling autoimmune disorder. The use of a
multivalent glycopolymer mimicking the natural HNK-1
epitope proved to be a valid approach to selectively sequester
the autoantibodies associated with anti-MAG neuropathy onset.
By applying a multivalent strategy, the inhibitory potential of
the monomeric carbohydrate epitope (KD 124–793 μM from
individual patient sera) could be improved by up to a factor of
230,000 in the multivalent display (KD 3.6–5.4 nM/epitope)
[84].
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